Howard A. "Skip" Burris, MD

Howard A. “Skip” Burris, III, MD, FASCO, FACP, discusses the integration of sacituzumab govitecan-hziy into the treatment landscape of metastatic triple-negative breast cancer.

Howard A. Burris, MD, also known as "Skip," of Sarah Cannon Research Institute, discussed how he wound up in the oncology space, his passion for getting to know and helping his patients, and some proud moments throughout his monumental career.

Howard A. "Skip" Burris, MD, president of Clinical Operations and chief medical officer at Sarah Cannon Research Institute, discusses updated findings from the MONALEESA-2 trial, which explored first-line treatment with ribociclib plus letrozole in patients with hormone receptor (HR)-positive, HER2-negative breast cancer.

Howard A. “Skip” Burris, MD, president of Clinical Operations and chief medical officer at Sarah Cannon Research Institute, a 2014 Giant of Cancer Care in Drug Development, discusses the biggest remaining challenges in treating patients with HER2-positive breast cancer.